Instil Bio, ImmuneOnco Ink License And Collaboration Agreement; Immuneonco To Receive Upfront Payment, Potential Near-term Payments Of Up To $50M Plus Potential Milestones Exceeding $2B
Instil Bio, ImmuneOnco Ink License And Collaboration Agreement; Immuneonco To Receive Upfront Payment, Potential Near-term Payments Of Up To $50M Plus Potential Milestones Exceeding $2B
Instil Bio和ImmuneOnco簽署許可和合作協議；ImmuneOnco將獲得前期付款，可能在短期內獲得高達5000萬美元的支付以及超過20億美元的潛在里程碑獎勵。
Instil is in-licensing ex-China development and commercial rights to ImmueOnco's proprietary PD-L1xVEGF bispecific antibody, IMM2510, as well as its next-generation anti-CTLA-4 antibody, IMM27M.
Instil正在許可ImmueOnco專有的PD-L1xVEGF雙特異性抗體IMM2510的中國以外開發和商業權利，以及其下一代的抗CTLA-4抗體IMM2700。
ImmuneOnco will receive an upfront payment and potential near-term payments of up to $50 million as well as potential additional development, regulatory, and commercial milestones exceeding $2 billion plus single digit to low double-digit percentage royalties on global ex-China sales.
ImmuneOnco將獲得高達5000萬美元的預付款和潛在的近期支付，以及可能超過20億美元的額外開發、監管和商業里程碑，以及全球（除中國）銷售額的個位數到兩位數的佣金。